Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Oxizen is a nutritional supplement softgel developed and marketed by Bal Pharma. It is formulated with a combination of flaxseed oil, folic acid (vitamin B9), and vitamin B12. Positioned within Bal Pharma's anti-diabetic portfolio, Oxizen is used as a supportive therapy to manage nutritional deficiencies and support overall metabolic, cardiovascular, and neurological health in patients with diabetes. Flaxseed oil provides essential omega-3 fatty acids (specifically alpha-linolenic acid) that support cardiovascular health and reduce inflammation. Folic acid and vitamin B12 are critical for red blood cell formation, DNA synthesis, and maintaining healthy nerve function, which is particularly beneficial in preventing or managing diabetic neuropathy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Oxizen.